Tags IDE Submission
Tag: IDE Submission
Vivos Inc. reports major progress in its India human trial for RadioGel®, showing high safety and localized tumor treatment precision.
Vivos Inc. advances cancer treatment with RadioGel® PRnT™ Human trials in India show early success, with Mayo Clinic expansion planned in 2025.
Vivos Inc. converts IDE submission to Pre-Sub filing with FDA approval, focusing on comprehensive review and risk/benefit analysis for Radiogel®
IsoPet® by Vivos Inc. (OTCQB: RDGL) uses Yttrium-90 for precise cancer treatment in animals. Learn about its technology, clinic expansion, and future plans.
Vivos Inc. advances with Reg A-1 filing to support human trials and expand animal therapies, reflecting growth potential and commitment to oncology innovation.
Vivos Inc. (RDGL) announces submission of IDE application to FDA for RadioGel™, advancing treatment for papillary thyroid cancer.
